ELGN-2112

DRUG2 trials

Sponsors

Elgan Pharma Ltd.

Conditions

Intestinal Malabsorption

Phase 2

Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

RecruitingNCT05904626

Elgan Pharma Ltd.Intestinal Malabsorption

Start: 2025-10-28End: 2027-06-01Target: 60Updated: 2026-04-09

Phase 3

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

RecruitingNCT05670951

Elgan Pharma Ltd.Intestinal Malabsorption

Start: 2025-02-27End: 2029-05-01Target: 360Updated: 2026-01-23